Results 151 to 160 of about 23,896 (206)

SingleNucleotide Polymorphisms as Biomarkers of Mepolizumab and Benralizumab Treatment Response in Severe Eosinophilic Asthma. [PDF]

Int J Mol Sci
Rojo-Tolosa S, Sánchez-Martínez JA, Caballero-Vázquez A, Pineda-Lancheros LE, González-Gutiérrez MV, Pérez-Ramírez C, Jiménez-Morales A, Morales-García C.   +7 more
europepmc   +1 more source

Benralizumab in severe eosinophilic asthma by biologic use and key clinical subgroups: real-world XALOC-1 programme: a plain language summary of publication. [PDF]

Immunotherapy
Jackson DJ, Pelaia G, Emmanuel B, Tran TN, Cohen D, Shih VH, Shavit A, Arbetter D, Katial R, Rabe APJ, Garcia Gil E, Pardal M, Nuevo J, Watt M, Boarino S, Kayaniyil S, Loureiro CC, Padilla-Galo A.   +17 more
europepmc   +1 more source

Very long-term data on patients with severe eosinophilic asthma treated with mepolizumab: a case series. [PDF]

Drugs Context
Lombardi C, Menzella F, Berti A.
europepmc   +1 more source

Durability of benralizumab effectiveness in severe eosinophilic asthma patients with and without chronic rhinosinusitis with nasal polyps: a <i>post hoc</i> analysis from the ANANKE study. [PDF]

Front Allergy
Brussino L, Aliani M, Altieri E, Bracciale P, Caiaffa MF, Cameli P, Canonica GW, Caruso C, Centanni S, De Michele F, Del Giacco S, Di Marco F, Malerba L, Menzella F, Pelaia G, Rogliani P, Romagnoli M, Schino P, Schroeder JW, Senna G, Vultaggio A, D'Amato M.   +21 more
europepmc   +1 more source

Sinonasal Outcomes Obtained after 2 Years of Treatment with Benralizumab in Patients with Severe Eosinophilic Asthma and CRSwNP: A "Real-Life" Observational Study. [PDF]

J Pers Med
De Corso E, Mele DA, Rizzi A, Spanu C, Corbò M, Pisciottano S, Mastrapasqua RF, Baroni S, Porru DP, De Maio G, Rizzuti A, Di Bella GA, Ortolan A, Bonini M, Cefaloni F, Boccabella C, Lombardi F, Chini R, Caruso C, Panfili M, Galli J.   +20 more
europepmc   +1 more source

IL-5 antagonism reverses priming and activation of eosinophils in severe eosinophilic asthma. [PDF]

Mucosal Immunol
Luo J, Chen W, Liu W, Jiang S, Ye Y, Shrimanker R, Hynes G, Klenerman P, Pavord ID, Xue L.   +9 more
europepmc   +1 more source

Editorial comment on "Benralizumab in children with severe eosinophilic asthma: Pharmacokinetics and long-term safety (TATE study)"

Cabrera-Perez, Javier S, Eigenmann, Philippe, Akenroye, Ayobami   +2 more
openalex   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Clusters of Severe Eosinophilic Asthma in a Korean Asthma Cohort

Respiration, 2021
<b><i>Background:</i></b> Targeted therapies have broadened the available treatment options for patients with severe eosinophilic asthma (SEA). However, differences in the magnitude of treatment responses among patients indicate the presence of various underlying pathophysiological processes and patient subgroups. <b><i&
Ji-Hyang Lee, Jin An, Ha-Kyeong Won, Bomi Seo, Jung-Hyun Kim, So-Young Park, Min-Hye Kim, Yoo Seob Shin, Jae-Woo Jung, Woo-Jung Song, Taehoon Lee, Hyouk-Soo Kwon, Jae Hyun Lee, Joo-Hee Kim, Sae-Hoon Kim, Yoon-Seok Chang, You Sook Cho, Dong-Ho Nahm, An-Soo Jang, Jung-Won Park, Ho-Joo Yoon, Sang-Heon Cho, Young-Joo Cho, Byoung Whui Choi, Hee-Bom Moon, Tae-Bum Kim   +25 more
openaire   +2 more sources